Berkshire, United Kingdom

Mark Richard Redfern

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Prokarium Limited. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Richard Redfern. Retrieved from https://idiyas.com/inventor/mark-richard-redfern

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mark Richard Redfern: Vaccine Vector Innovation

Introduction

Mark Richard Redfern is an inventor associated with Berkshire, Great Britain, and Prokarium Limited. His patent work concerns an attenuated vaccine vector designed to present immunogenic peptides from Chlamydia.

Latest Patents

The available information identifies one patent associated with Redfern. The invention describes an attenuated vaccine vector containing one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. One embodiment includes aroC and ssaV attenuating mutations, with the peptide-encoding polynucleotides controlled by an inducible promoter, such as the ssaG promoter. The disclosed peptides may include PmpG peptides, including CT110, CT84, or CT40. The record lists 1 patent.

Career Highlights

Redfern’s listed patent work is connected to Prokarium Limited and focuses on vaccine-vector design. The described approach combines attenuation mutations with inducible expression of Chlamydial antigens.

Collaborations

The provided information names Jonathan Lewis Telfer and Michael Joseph Lacy as Redfern’s coworkers. Their inclusion indicates professional connections, but the available details do not specify their roles in the patent.

Conclusion

Mark Richard Redfern’s recorded invention addresses an attenuated vaccine-vector approach for delivering immunogenic Chlamydial peptides, reflecting his patent-related work with Prokarium Limited.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…